Humacyte Stock Forecast
NASDAQ: HUMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 10:47 AM ET
HUMA analyst consensus
Consensus (6 analysts)
buy
Avg. price target
$1.63+262.14%
- Strong buy 1
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Humacyte (2026-10-08), 4 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $1.63, with a high estimate of $4.00 and a low estimate of $0.50. The average target implies upside of 262.1% from the current price of $0.4501.
The spread between the highest and lowest targets is 700.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for HUMA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 17% |
| Buy | 3 | 50% |
| Hold | 2 | 33% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $0.50 | +11.09% |
| Average target | $1.63 | +262.14% |
| High target | $4.00 | +788.69% |